CD8^+CD28^-Ts、CD3^+CD56+NKT细胞在B细胞非霍奇金淋巴瘤患者外周血中分布的分析

Distribution of CD8^+CD28^-T Cells and CD3^+CD56^+NKT Cells in Peripheral Blood of Patients with B-cell Non-Hodgkin's Lymphoma

背景及目的:目前认为B细胞非霍奇金淋巴瘤(B-NHL)常伴随免疫抑制,CD8+CD28-Ts(Ts)细胞和CD3+CD56+NKT(NKT)是新鉴定的新型免疫抑制性调节细胞,在肿瘤的免疫抑制及免疫逃逸机制中起重要作用,但它们在B细胞淋巴瘤患者外周血的分布情况及其免疫抑制中的作用目前尚不清楚。本文通过分析两者在化疗前及化疗后B-NHL患者外周血中比例及变化规律,初步探讨它们在B-NHL的免疫抑制作用及其影响因素,为有效干预患者的免疫功能提供参考。方法:应用流式细胞仪检测79例治疗前的B-NHL患者、经4～6周期化疗后完全缓解(CR)的18例患者、30例健康志愿者外周静脉血中NKT及Ts细胞的比例。结果:在79例治疗前B-NHL患者的外周血中,Ts细胞比例为(18.19±5.03)%,较正常对照组(11.20±3.49)%明显增高(P<0.01);NKT的比例为(6.08±3.29)%,亦较正常对照组的(3.52±1.56)%明显增高(P<0.01)。Ts在不同临床分期的患者之间无显著性差异P>0.05;Ⅰ期为(17.56±4.10)%、Ⅱ期为(18.05±5.64)%、Ⅲ期为(18.14±5.58)%、Ⅳ期为(18.95±4.64)%;在不同恶性程度的患者之间亦无显著性差异P>0.05;低度恶性为(17.81±5.24)%、中度恶性为(18.37±4.83)%、高度恶性为(18.31±5.93)%;在治疗前(18.64±4.55)%和CR后(19.42±4.95)

BACKGROUND &OBJECTIVE: Patients with B-cell non-Hodgkins lym ph oma (B-NHL) usually have a poor immune response. CD8+CD28-T cells (Ts) and CD 3+CD56+NKT cells (NKT) are new types of immune suppressor cells. This study wa s to analyze proportions and changes of them in peripheral blood of patients wit h B-NHL, explore their effects on immunosuppression of B-NHL, and the influnce factors, to provide reference for intervening in immune function of B-NHL pati ents. METHODS: Peripheral blood samples were got from 79 naive patients with B-NHL before treatment, and 25 healthy people, samples of 18 patients who got comp lete remission (CR) after 4-6 cycles of chemotherapy were collected either befo re chemotherapy or after CR. Proportions of Ts and NKT were analyzed by flow cyt ometry (FCM). RESULTS: Compared with control group, proportions of Ts,and NKT in peripheral blood of B-NHL patients before chemotherapy were (18.19±5.03)%,an d (6.08±3.29)%, significantly higher than those of healthy people [(11.20±3.4 9)%, P< 0.01; (3.52±1.56)%,P< 0.01]. There were no significant differences of proportions of Ts among patients with B-NHL of different clinical stages (P >0 .05),and different malignant grade (P >0.05), and between before treatment and after CR (P=0.55). No significant difference of proportions of NKT was found am ong patients with B-NHL of different clinical stages (P >0.05), and different m alignant grade (P >0.05), and between before treatment and after CR (P=0.39). CO NCLUSION: Populations of Ts and NKT commonly increased in peripheral blood of pa tients with B-NHL, they may play roles in immunosuppression of B-NHL.